Dhanir Tailor, Ph.D., left, Sanjay Malhotra, Ph.D., and Arpit Dheeraj, Ph.D., are among the developers of the first drug that targets YB-1, an important signaling point in many different cancers. The drug has shown powerful anti-tumor activity in animal models of several different tumor types. (OHSU/Christine Torres Hicks)
